New blood test could reduce unnecessary transfusions in liver shunt patients
NCT ID NCT04421924
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a special blood test called thrombelastography can help doctors decide when to give blood products to people with liver cirrhosis who are getting a TIPS shunt. The goal is to see if this test reduces the amount of blood products used and prevents bleeding complications. About 39 adults with liver cirrhosis who need a TIPS shunt will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 39 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2020
- Expected to finish
-
May 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
inclusion criteria * Liver cirrhosis * \>18 years * Indication for TIPS implantation * Ability to sign informed consent exclusion criteria * Contraindications against TIPS implantation * Hepatocellular carcinoma BCLC D * Ongoing bleeding * pre-existing anticoagulant therapy at time of inclusion * administration of blood products within 1 week prior to the enrolment * Other malignancies that lead to an impaired 90-day survival * Inherit blood clotting disorders * Hepatic encephalopathy grade 3 or 4 * any other condition or circumstance, which, in the opinion of the investigator, would affect the patient's ability to participate in the protocol
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Liver cirrhosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Department of Internal Medicine, Medical University of Graz
RECRUITINGGraz, 8010, Austria
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria in a capsule: a new attempt to calm a brain complication of cirrhosis
- Can a digital platform catch liver cancer sooner?
- Can a Two-Drug combo keep cirrhosis patients out of the hospital?
- Can removing the spleen help the liver fight cancer?
- Blood test may forecast which cirrhosis patients survive after discharge
- Can a parasite drug help fight a deadly gut infection in cirrhosis?